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Abstract
Quantum dots (QDs), nano-carriers for drugs, can help realize the targeting of drugs, and improve the bioavailability
of drugs in biological fields. And, a QD nano-carrier system for drugs has the potential to realize early detection,
monitoring, and localized treatments of specific disease sites. In addition, QD nano-carrier systems for drugs can
improve stability of drugs, lengthen circulation time in vivo, enhance targeted absorption, and improve the distribution
and metabolism process of drugs in organization. So, the development of QD nano-carriers for drugs has become a
hotspot in the fields of nano-drug research in recent years. In this paper, we review the advantages and applications of
the QD nano-carriers for drugs in biological fields.
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Nowadays, many anti-tumor drugs in clinical tests have
various side effects, such as non-selective, toxicity, poor
targeting, etc. [1]. So, the heavy side effects of normal tis-
sues produced by a conventional therapeutic dose of anti-
tumor drugs would reduce drug efficacy [2]. Severe side
effects arise from the use of classical cancer therapeutics
due to non-specificity of the cancer drugs, resulting in high
toxicity in noncancerous but rapidly dividing cells [3]. Due
to the lack of any bioluminescence, tumors can be difficult
to be located and removed, particularly on smaller size
scales. Therefore, it is highly desirable to create a means by
which cancer cells could be targeted with high specificity
and be simultaneously imaged in vivo [4]. Nano-carriers
for drugs mainly have nano-vehicles (including liposomes,
etc.), polymer nanoparticles/nano-capsules, microemul-
sion/nano-emulsion, micelles, dendrimers, and inorganic
nano-carriers (such as silica nano-spheres, nano-tubes, and
quantum dots [QDs]) [5, 6]. QDs possess unique optical
properties that make them potential candidates as lumi-
nescent nano-probes and carriers for biological applica-
tions. Drugs can be loaded into QD nano-carriers for
drugs by the means of dissolving, dispersing, adsorption
and coupling, etc. [5, 7]. Then, the physical and chem-
ical properties (such as saturation solubility, dissolution
rate, crystal form, particle surface hydrophobicity, and
hydrophilicity), physical response, and biological char-
acteristics of drugs are changed due to the role of the
carriers; thus, the absorption, distribution, metabolism,
and excretion of drugs are affected [8]. Ultimately, QD
nano-carriers for drugs can enhance the efficacy and
reduce side effects of drug reactions to improve the
therapeutic index of the drugs [9]. Moreover, nano-
carriers for drugs can effectively promote the absorp-
tion of small molecule drugs. At the same time, the
research about macromolecular drug delivery has also
demonstrated good prospects [10].
As a new kind of inorganic nano-fluorescent probe,
QDs have showed outstanding advantages in the long-
time, multi-color fluorescence imaging and detection
[11, 12]. The development of QD labeling promotes the
research in the nano-drugs in cellular, even at live ani-
mal level. The development of fluorescence imaging
technology of QDs and the therapy-based multifunc-
tional nano-drugs is expected to apply to diagnosis and
treatment of cancers [13, 14]. At the same time, surface
modifications with targeting ligands are also commonly
used to increase drug-delivery efficiency [15]. After al-
most 10 years of development, the technology of QDs
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surface modifications has realized relative improvements.
The surface ligands can be thioglycolic acid, cysteamine or
polyethylene glycol (PEG), and water-soluble polymers
with carboxyl, which can bind the drug molecules with
QDs through electrostatic binding or covalent bond and
form nano-drug complexes carriers, and then realize fluor-
escent trace of drug molecules in cells or animals [16].
Advantages of QDs as Nano-Carriers in Targeted Drug
Delivery
Compared with conventional drug carriers, nano-carriers
for drugs have many advantages, such as smaller size, larger
specific surface area, higher and more reactivity activity
center, stronger adsorption capacity and other characteris-
tics [17, 18]. (l) Drug-loaded nano-particle carriers targeted
delivery of drugs to specific organs by modifying antibodies,
aptamer, folic acid and other biological molecules. (2)
Nano-particle carriers have relatively unique mode of con-
trolling and releasing drugs. At the beginning, the mode of
controlling and releasing drugs of nano-particle carriers is
generally an outbreak release, and then it shows a constant
release for a long period of time. Therefore, nano-carriers
for drugs can significantly extend the effectivity of drugs at
limited concentration, deliver at fewer intervals, and lower
doses and reduce side effects and the suffering of patients.
(3) Since the drug-loaded nano-particle carriers have the
property of adhesion and small particle size, it is possible to
extend drug stay in local tissues or sites, increase contact
area of drugs and improve the absorption and bioavailabil-
ity of oral drugs. (4) Drug-loaded nano-particle carriers can
prevent rapid degradation of drugs by the digestive en-
zymes in the body in the process of conveying improved
stability and utilization of drugs. (5) Drug-loaded nano-
particle carriers can alter the mechanisms of membrane
transport and enhance the permeability of drugs in bio-
film, and then improve absorption effects of the drugs in
cells. (6) The nanoparticles as carriers can modify the ori-
ginal drug to enhance water-solubility or get targeted and
sustained release function, thereby enhance the efficacy of
anticancer and reduce side effects of drugs.
Applications of Quantum Dot Nano-Carriers for Drugs
Ideal QD nano-carrier materials for drugs should have the
following properties [19]: (1) no reaction with drugs, (2)
high drug loading capacity and encapsulation efficiency,
(3) appropriate preparation and purification method (4)
good biocompatibility and low toxicity, (5) certain mech-
anical strength and stability and appropriate particle size
and shape, (6) longer residence time in vivo. At present,
the commonly used anticancer nano-carriers for drugs are
mainly liposome, chitosan, silica nanoparticles, and poly-
mer nanoparticles.
QDs have unique optical properties, due to their
quantum effect and size effect. When the particle size is
of nanometer scale, it will cause quantum confinement
effect, size effect, dielectric confinement effect, macro-
scopic quantum tunneling effect, and surface effect.
Consequently, QDs exhibit many optical properties, and
have a very broad application prospect in biological
fluorescent probes and functional materials. Therefore,
QDs will have a meaningful effect on the continued de-
velopment of life sciences.
To our knowledge, an important aspect of developing
modified QDs in biomedical applications is their selective
targeting. Generally, in recent years, tumor cell targeting
in both therapeutic and diagnostic applications have only
focused on a small number of candidate ligands whose
receptors are over-expressed in tumor cells, such as folic
acid and delivery of siRNA. One such receptor is folic
acid, which has widely been used as a targeting ligand to
deliver therapeutic agents to cancer cells due to its high
binding affinity with folate receptor (FR). And, studying
siRNA delivery in cells and small animals using QDs
should be an excellent choice because of QDs’ intrinsic
fluorescence and their unique optical properties (e.g., tun-
able emission, photostability, and brightness).
Folic Acid-Quantum Dot Complexes
Folate (folic acid, FA), which is a donor number of car-
bon unit in vivo, is a necessary material to biosynthe-
size nucleic acids, amino and pantothenic acid, and its
structure is shown in Fig. 1. FA is a needed vitamin for
everyone, and it not only can participate in a variety of
metabolic pathways of one-carbon transfer reactions,
but also is the targeting ligand of FR. With the develop-
ment of molecular biology and molecular medicine and
in-depth study of tumor molecular level, researchers
have found a series of receptors associated with tumor
growth on the surface of tumor cells or tumor-
associated blood vessels, and found the receptors high
affinity to combine with its ligands. Therefore, ligands
as targeting molecules of drug carriers can enhance
therapeutic efficacy via a receptor-mediating mechan-
ism, and then to achieve targeted therapy. FR is highly
expressed in most tumor cells (such as ovarian cancer,
cervical cancer, endometrial cancer, breast cancer, colon
cancer, lung cancer, nasopharyngeal carcinoma choroid,
and ependymal cell tumor cells), so as a low molecular
weight targeting molecule, FA quickly becomes a hot
topic of research [20]. Studies have shown that FA
complexes modified by carboxyl deuterogenic remained
a strong binding capacity with FR [21]. Typically, pro-
tein toxins, small molecule chemotherapeutic agents,
radio-therapeutic agents, polymer-wrapped drugs, gene
carriers, pro-drug inhibitors, and immunotherapeutic
agents can form multimeric complexes bound with FA
by covalent coupling. These FA complexes have better
targeting ability and more therapeutic effect than the
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original drug, so the FA complexes have higher poten-
tial for drug delivery system [22, 23].
FA, as a guiding molecule of anti-tumor drugs, has
many advantages, such as low cost, high chemical stability,
good receptor affinity, small size conducive to enter tumor
cells through blood vessels, and completely infiltrate
tumor tissues, etc., besides, FA complexes can well target
to tumor cells. Now FA complexes have shown obvious
advantages in targeting diagnosis and treatment on cancer.
HSV-TK/GCV suicide gene systems are combined with
near-infrared QDs, and the former is quite effective in
liver cancer treatment, the latter facilitates tumor imaging
[24]. A folate-modified theranostic (FL/QD-TK) was com-
posed of an HSV-TK suicide gene covalently coupled with
near-infrared fluorescent CdSeTe/ZnS core/shell QDs.
FL/QD-TK exhibited highly specific tumor imaging and
strong inhibition of the FR-over-expressed Bel-7402 mouse
xenografts without systematic toxicity (Fig. 2) [24]. The fa-
cile surface-functionalization of one type of biocompatible,
oligomeric nanoparticles 1-NPs binds with NIR-emitting
CdTe/CdS QDs and folate could obtain tumor-targeted
imaging in vivo (Fig. 3) [25]. As-prepared nanoparticles
showed excellent targeting property to FR-expressing
tumor cells in vitro and were successfully applied to select-
ively imaging FR over-expressing tumors in vivo.
Currently, as the tumor diagnosis materials, FA com-
plexes have made some breakthroughs. For example
some FA complexes coupled with radioactive elements
(Fig. 4) have been used for clinical diagnosis of ovarian
cancer [26]. But, the anti-tumor research about FA com-
plexes in vivo was just the beginning. And, because FA
complex structure and composition are complex, their
metabolism and excretion in vivo, physiological function,
stability, and toxicity are uncertain. In addition, some
researchers consider that the release and treatment ef-
fects of drugs in FA complexes remain unsatisfactory in
tumor tissues, so a lot of researches should be done
before the FA complexes are used in clinical treatment
of cancers. Along with widespread applications of QDs
in biomedicine, more different fluorescent QDs made of
FA complexes would be prepared for tumor diagnosis.
Quantum Dots in RNA Interference (RNAi) Applications
Since RNAi was reported in Caenorhabditis elegans, RNAi
phenomena were found in many organisms, such as zeb-
rafish [27], fungi [28], drosophila [29], and mammalian
mouse embryos [30]. However, the RNAi phenomenon
was not found in archaea and prokaryotes; thus, it is pos-
sible that the RNAi is a means for advanced bio-specific
to regulate gene expression and resist viruses or inhibit
transposon-induced mutations [31, 32].
Small interfering RNA (siRNA) is quickly becoming a
new tool for gene functional research and the new means
of treatment [33]. After binding siRNA duplexes, RNA-
induced silencing complex (RISC) was cleaved single-
stranded siRNA. The targeted homology mRNAs binded
with siRNA single strand are sheared by RISC to achieve
the purpose of gene silencing. Now siRNA can enter cells
like ribozyme by chemical synthesis or express short
hairpin-like RNA (shRNA) by a carrier, and the latter can
be transformed into siRNA in the cell to silence the re-
lated gene. Some studies have shown that there are other
siRNA-silencing mechanisms, for example, siRNAs can
lead to transcriptional gene silencing by RNAi-modified
cellular chromatin in biology [34, 35]. RNAi as a new
method of gene therapy has aroused the interest of many
researchers [36], mainly because of low toxicity and speci-
ficity of RNAi, which is an endogenous regulation of gene
expression substance in cells, and the other reason is that
RNAi has higher gene silencing efficiency than that of
ribozyme.
The QD delivery systems are widely used to carry and
image on siRNA in vivo and in vitro due to their inher-
ent excellent optical properties. QDs are the ideal tool
for discovering and validating in cells and small animals,
but their potential uses in humans as drug delivery vehi-
cles are unclear at present because bio-conjugated QDs
cannot be efficiently cleared from the body either as
intact particles or as ions [37, 38]. The large surface area
of the amine-terminated nano-complex presents plenty
of opportunities for further bio-functionalization while
maintaining a high siRNA loading efficiency [37]. For ex-
ample, the Mn:ZnSe d-dot can be used as a biocompatible
Fig. 1 The scheme of folic acid
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nano-carrier for gene delivery in vitro (Fig. 5) [39]. Using a
d-dot/polymer nano-complex as a transfection agent, siR-
NAs targeting the mutant oncogenic K-Ras gene were de-
livered into pancreatic cancer cells for sequence-specific
gene therapy. The prepared nano-complex formulation
achieved high gene transfection efficiency. Therapeutic ef-
fect was confirmed by the suppressed expression of the
mutant K-Ras gene at the mRNA level. And, the d-dot/
PAH nano-complex formulation is highly biocompatible
even at a concentration as high as 160 μg mL−1, so the
d-dots can act as a promising candidate for biomedical
applications. And, the nano-complex can be functional-
ized with FA for receptor mediated cancer cell targeting
and gene delivery.
SiRNA-aptamer chimeras are emerging as a highly
promising approach for cell-type-specific delivery of
siRNA due to the outstanding targeting capability of apta-
mers and the compatibility of chimeras with native ribo-
nuclease (Dicer) processing [40]. For efficient RNAi, some
challenges must be addressed, for example, how to get
siRNA from the endosome after entering cells and how to
retain aptamer targeting specificity when chimeras are
combined with delivery carriers. Since both siRNA and
aptamer are RNA molecules and often share similar
molecular weight, so it is hard to design cationic delivery
vehicles that selectively bind to the siRNA, leaving the
targeting exposed aptamer. A rationally designed nano-
particle carrier that simultaneously displays large surface
Fig. 2 Real-time imaging of FL/QD-TK in Bel-7402 tumor xenograft model [24]
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area for high siRNA payload, exposed aptamer for specific
targeting, proton sponge effect for endosome escape, and
fluorescence for imaging and quantification were reported
(Fig. 6) [40]. This method improved gene silencing effi-
ciency over the conventional approaches based on simple
mixing of siRNA-aptamer chimeras with cationic nano-
particles. This remarkable difference in RNAi efficiency
using nano-particle-chimera complexes is directly related
to cell uptake discrepancy resulting from aptamer con-
formation on nano-particle surface (intact vs. random).
In recent years, along with the emergence of stable
expression carriers, the improvement of transfection effi-
ciency, siRNA can stably express after transfecting and
screening and can maintain interference effect for a long
time, so that the applications of siRNA are more widely
in functional genomics and gene therapy. However, there
Fig. 3 Schematic illustration of the preparative procedures of 1-NPs-QDs-FA [25]
Fig. 4 A scheme of folate-targeted DOX nano-aggregates with DOX-PEG-FOL conjugate, FOL folate [26]
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are some challenges about siRNAs used in clinical treat-
ment, such as how to use the best way to import siRNAs
intracellular, how to get more efficiency, and how to
avoid missing target phenomenon and nonspecific reac-
tions. Therefore, further study in RNAi mechanism will
not only enrich our understanding of the regulation of
gene expressions, but also facilitate practical applications
of gene therapy.
The Use of Duantum Dots in Studying Drug Release
Traditional methods of studying nano-drug release in vivo
mainly determine the total content of drugs by HPLC-MS
and other means, but these methods are often problematic
at actual work. For example, it is difficult to quantify free
drugs and encapsulated drugs separately, and there are
technical difficulties in quantifying some trace drugs under
the background of complex organisms. Recently, the QD-
FRET (Förster resonance energy transfer) method pro-
vides a new way to solve these problems. The principle of
QD-FRET method is when the fluorescence emission
spectrum of QDs and the excitation spectrum of fluores-
cent receptors overlap and the spatial distance between
the donor and acceptor is close enough, the QDs at states
of excitation can be used as a fluorescence donor to
Fig. 6 Schematic representation of cationic nanoparticles for targeted delivery of siRNA-aptamer chimeras [40]
Fig. 5 Schematic illustration of preparation steps of the Mn:ZnSe QD-based siRNA carriers [39]
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transfer fluorescence energy to the acceptor, which re-
sults in fluorescence quenching of the QDs donor and
fluorescence enhancement of the acceptor. This energy
transfer usually occurs when the distance of intermole-
cules is 1–10 nm, and the efficiency of energy transfer
closely relates to the distance between each other, namely,
the smaller the distance, the higher the FRET efficiency.
This technology has been successfully applied in inter-
action studies of biological macromolecules, immunoassay,
nano-sensor design, and other fields [41, 42]. Recently, the
researchers have made some progress at nano-drugs
release [17].
In addition, the two-FRET system of QDs could release
Dox in cells (Fig. 7) [43]. The identified prostate-specific
membrane antigen A10 RNA aptamer were coated on the
QD surface, and then they were mixed with Dox solution
to make Dox inserted into the inner aptamer duplex to
form QD-aptamer (Dox) complexes. The donor-acceptor
Fig. 7 Schematic illustration of QD-aptamer (Dox) Bi-FRET system [43]
Fig. 8 Schematic of the preparation of QD-PEG-ADM and the mechanism of this system for drug release [45]
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consisting of Dox and QDs by cutting role and the
donor-quenching body double FRET system consisting
of Dox and aptamer resulted in reversible fluorescence
self-quenching of complexes. With the extension of in-
cubation time, and after the complexes are recognized
and taken by prostate tumor cells, Dox is released
from the complexes, and the fluorescence signals of
QDs and Dox are significantly increased in cells. Both
tumor cell localization and intracellular Dox release
testing can be achieved by measuring the fluorescence
signal changes.
A wide variety of both water-soluble and insoluble drugs
can be incorporated into nanoparticles with a high effi-
ciency and modifiable drug loadings. Using QDs as drug
models and imaging labels to evaluate nano-particle for-
mulations incorporating both hydrophilic and hydropho-
bic drugs and imaging agents is developed. The use of
QDs enables efficient detection and precise quantization
of cellular uptake of particles. The correlation of QDs-
and doxorubicin-incorporated nanoparticles is useful to
develop an evaluation platform for nano-particle formula-
tions through imaging and quantization [44]. QDs can be
used as a model for such non-fluorescent drugs, and QD-
PNPs can be used as a model to monitor the position of
used polymer and evaluate the efficacy of the proposed
delivery system. Moreover, QDs can be used as visible ring
surrounding the micro-particles to study micro-particle
theranostic delivery formulations by deliberately incorpor-
ating, for they are easy to be identified and traced in diag-
nostic and chemotherapeutic applications.
An effective and facile FRET-based QD-PEG-Dox drug
delivery system (DDS) has been used for real-time moni-
toring of the release of loaded drugs (ADM) in situ (Fig. 8)
[45]. An outstanding correlation between the FRET signal
and drug release in different pH environments has been
applied to real-time detection of (Dox). The methods of
ratiometric and time-resolved fluorometry are practical
for real-time monitoring of drug release in tumor cells. It
would promote the development of versatile DDS, and
offering a sensitive and efficient method to monitor in
real-time the release in situ of drugs, especially in physio-
logical microenvironments.
Conclusions
Although the research of QD nano-carriers for drugs
has achieved some developments, the application of QD
nano-carriers for drugs is still at the beginning. Using
the QD nano-carriers for drugs in biology is a burgeon-
ing new field but has high value. Along with the con-
tinuous development of the technique of QD nano-
carriers for drugs, new development opportunities for
drug screening, disease screening, and gene sequencing,
plurality of biomedical research will come.
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